tiziana-logo.png
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
October 16, 2023 07:00 ET | Tiziana Life Sciences Ltd.
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and...
Figure 1
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
October 13, 2023 07:00 ET | Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
cmi_logo.png
[Latest] Global Mental Health Technology Market Size/Share Worth USD 18.9 Billion by 2032 at a 16% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 25, 2023 18:30 ET | Custom Market Insights
Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Mental Health Technology Market Size, Trends and Insights By Functionality...
Full Logo - OKYO .jpg
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023 07:00 ET | OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
Full Logo - OKYO .jpg
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
August 30, 2023 07:00 ET | OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
logo.png
Clinical Chemistry Analyzers Market Size to Worth USD 24.8 BN by 2032
August 18, 2023 10:45 ET | Precedence Research
Ottawa, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The global clinical chemistry analyzers market size was valued at USD 14.63 billion in 2022. The advancement of the technologies behind clinical chemistry...
GMILogo_Vertical-Gradient.png
Disposable Endoscopes Market to hit USD 9.7 billion by 2032, says Global Market Insights Inc.
August 13, 2023 21:30 ET | Global Market Insights Inc.
Selbyville, Delaware, Aug. 13, 2023 (GLOBE NEWSWIRE) -- Disposable Endoscopes Market size is expected to reach USD 9.7 billion by 2032. The industry is driven by technological advancements in the...
cmi_logo.png
[Latest] Global Patient Simulator Market Size/Share Worth USD 1,421.5 Million by 2032 at a 8.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 01, 2023 12:30 ET | Custom Market Insights
Austin, TX, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Patient Simulator Market Size, Trends and Insights By Product Type (Adult...
HeartFlow Logo.png
New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions
July 28, 2023 09:30 ET | HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of...
Full Logo - OKYO .jpg
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         
July 28, 2023 07:01 ET | OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...